Differential effects of XXXX application on @entity20351 expression in organotypic slices of @entity35 prefrontal cortex.

@entity1 @entity20351 @entity2227 @entity12781 @entity212 @entity70588 @entity161 @entity179 @entity35 @entity1928
@entity12781 ( @entity212 ) is a non-competitive NMDA @entity2227 receptor antagonist that induces psychotomimetic effects in @entity1 and experimental animals. Chronic @entity212 exposure elicits signs of persistently altered frontal brain activity and related behaviors which are also seen in @entity1 with @entity161 . @entity20351 ( @entity20351 ) belongs to the chromogranin family of proteins that exist in large dense core vesicles in nervous tissue. In the brain, 90% of @entity20351 is processed to the small peptide secretoneurin. We previously detected differential effects of single-dose and subchronic @entity212 administration on @entity20351 expression in the @entity35 prefrontal cortex (PFC). In the present study, we applied @entity212 to organotypic PFC slices. @entity212 application for 28 h induced decreased tissue and culture medium secretoneurin content. In contrast, incubation with the adenylate cyclase activator @entity1928 caused significantly increased @entity70588 levels after 8 h. @entity212 for 4 h followed by 24 h without @entity212 resulted in increased culture medium secretoneurin content but no change in tissue levels. @entity20351 mRNA expression was decreased after 28 h @entity212 application in cortical neurons. Immunohistochemical and TUNEL staining profiles indicated that the alterations were not due to @entity179 . @entity212 for 5 days changed neither the secretoneurin tissue or culture medium levels, nor the @entity20351 mRNA expression. These results demonstrate that @entity212 modulates @entity20351 expression in PFC tissue in the absence of afferent inputs and that the nature of these changes is dependent upon the duration of exposure to and/or withdrawal from @entity212 .
